Contribute Try STAT+ Today

WASHINGTON — Nearly everyone here expected President Biden to move with record speed to nominate someone to lead the Food and Drug Administration.

As the coronavirus pandemic raged, lobbyists, patient advocates and public health experts hypothesized the position would be one of the earlier picks. Biden nominated Xavier Becerra to lead the health department, for example, in December, before his picks for the Centers for Medicare and Medicaid Services and assistant secretary for health.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Biden probably put the job out for bids and he is now sorting through the various payoffs.

  • Biden is a fool. He seems to value politics more than substance. He won’t find a candidate better than Janet Woodcock.

    • Janet’s got a lot of tenure with the agency, but she tarnished her brand by advocating for Sarepta’s drug exonydys 51 when the data and the FDA’s own advisory council indicated there was negligible or no benefit to the drug. Follow the money.

Comments are closed.